Home › Calculator › RVVTF Dividend Calculator 2026
RVVTF Dividend DRIP Calculator 2026
10526.32% YieldHealthcareRevive Therapeutics Ltd. · OTC
Price: $0.02 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When RVVTF pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your RVVTF snowball 📈
$10,000 in RVVTF → $1835807669584918784.00M in 10 years · $151,544,301,600,207,900,000,000.00/month
About Revive Therapeutics Ltd. (RVVTF) — Dividend Analysis 2026
Revive Therapeutics Ltd., a life sciences firm founded in 2012 and headquartered in Toronto, Canada, is focused on discovering and advancing treatments for uncommon diseases and infectious illnesses. The company maintains a pharmaceutical pipeline centered on cannabinoids, specifically targeting rare inflammatory conditions. Key developments in its therapeutic portfolio include: Bucillamine: Currently in Phase 3 clinical trials, it is being investigated for combating infectious diseases such as influenza and COVID-19. Psilocybin: This compound is in Phase 1 clinical studies for its potential in treating methamphetamine use disorder. Psilocin: The company is exploring its application for a range of mental health challenges, including depression, anxiety, bipolar disorder, bulimia, and anorexia nervosa. Cannabidiol (CBD): This is under investigation for its use in autoimmune hepatitis and for reducing ischemia and reperfusion injury that can occur after organ transplantation. Revive Therapeutics Ltd. also engages in several strategic research partnerships. These collaborations include an alliance with PharmaTher Inc. to develop psilocybin for cancer treatment and to identify new applications for other psychedelic compounds; a project with North Carolina State University to create a biosynthetic version of psilocybin through an enzymatic platform; a joint effort with the University of California, San Francisco, to assess Bucillamine's effectiveness against severe COVID-19; clinical research into psychedelics with the University of Health Sciences Antigua; and another collaboration with PharmaTher for the advancement of a psilocybin microneedle patch.
Compare RVVTF with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full RVVTF DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open RVVTF position with:
🌍 RVVTF Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold RVVTF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 10526.32% | 10523.52% | $1,052,632 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 8947.37% | 8944.57% | $894,737 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 8421.06% | 8418.26% | $842,106 / yr |
| 🇬🇧 UK ISA | 0% | 10526.32% | 10523.52% | $1,052,632 / yr |
| 🇬🇧 UK Taxable | 8.75% | 9605.27% | 9602.47% | $960,527 / yr |
| 🇨🇦 TFSA | 0% | 10526.32% | 10523.52% | $1,052,632 / yr |
| 🇨🇦 CA Taxable | 25% | 7894.74% | 7891.94% | $789,474 / yr |
| 🇦🇺 Super (pension) | 15% | 8947.37% | 8944.57% | $894,737 / yr |
| 🇦🇺 AU Taxable | 30% | 7368.42% | 7365.62% | $736,842 / yr |
| 🇩🇪 DE Taxable | 26.375% | 7750.00% | 7747.20% | $775,000 / yr |
| 🇫🇷 FR Taxable | 30% | 7368.42% | 7365.62% | $736,842 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 RVVTF Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 RVVTF Dividend Payment Schedule
RVVTF pays quarterly — 4 times per year. Next ex-div: TBD.
📊 RVVTF vs Healthcare Benchmarks
How RVVTF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for RVVTF sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ RVVTF Insider Activity
No recent SEC filings reported in the last 90 days.Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the RVVTF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Revive Therapeutics Ltd. (RVVTF) is currently trading at $0.02, 96% below its 52-week high. The current dividend yield is 10526.32% based on an annual payout of $2.00 per share.
RVVTF (Revive Therapeutics Ltd.) — 10526.32% Dividend Yield Analysis
Revive Therapeutics Ltd. (RVVTF) is a healthcare stock currently trading at $0.02 with a dividend yield of 10526.32%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (10526.32%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.